CNAT - Conatus Pharmaceuticals EPS in-line misses on revenue November, 01 2018 04:12 PM Conatus Pharmaceuticals Conatus Pharmaceuticals (NASDAQ:CNAT): Q3 GAAP EPS of -$0.15 in-line. Revenue of $7.66M (-19.9% Y/Y) misses by $2.12M. Press Release More news on: Conatus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, ,